Soleno Therapeutics Regains Compliance with NASDAQ

Soleno Therapeutics (NASDAQ:SLNO) received a notice from the NASDAQ Listing Qualifications Staff regarding the regaining of its compliance with the exchange.
As quoted in the press release:

[T]he Company that it regained compliance with NASDAQ’s minimum bid price requirement under NASDAQ Listing Rule 5550(a)(2) for continued listing on The NASDAQ Capital Market. Accordingly, Soleno Therapeutics is in compliance with all applicable listing standards and its common stock will continue to be listed on The NASDAQ Capital Market and NASDAQ considers the matter closed.

Click here to read the full press release.

Source: globenewswire.com